

# After-Sensations and Lingering Pain Following Examination in Patients with Fibromyalgia Syndrome

Richard J. Berwick MA<sup>1,3\*</sup>, David A. Andersson PhD<sup>2</sup>, Andreas Goebel PhD<sup>1,3#</sup>, Andrew Marshall PhD<sup>1,3#</sup>

<sup>1</sup> Pain Research Institute, University of Liverpool, UK

<sup>2</sup> Wolfson Centre for Age-Related Disorders, King's College London, UK

<sup>3</sup> Walton Centre, Longmore Lane, Liverpool, UK

#AG and AM contributed equally

\*Corresponding author:

[richard.berwick@liverpool.ac.uk](mailto:richard.berwick@liverpool.ac.uk)

ORCID id: <https://orcid.org/0000-0002-6895-6127>

Telephone: 0151 529 5835

**Running Title: After-sensations in Fibromyalgia Syndrome**

## Summary:

In fibromyalgia syndrome, after-sensations following termination of an innocuous brushstroke stimulus persist and are often uncomfortable. This has important implications for patient education and examination.

© The Author(s) 2022. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

Fibromyalgia syndrome (FMS) is a chronic widespread pain condition with mixed peripheral and central contributions. Patients display hypersensitivities to a spectrum of stimuli. Patients' blunt pressure pain thresholds are typically reduced, and sometimes (~15%) gentle brushstroke induces allodynia. However, after-sensations following these stimuli have not, to our knowledge, been reported.

We examined the perception of blunt pressure and 'pleasant touch' in FMS. Patients were first interviewed and completed standard psychometric questionnaires. We then measured their sensitivity to blunt pressure and perception of pleasant touch including after-sensations; patients were followed for five days evaluating lingering pain from blunt pressure.

We recruited 51 FMS patients and 16 pain-free controls (HC) at a UK Pain Management Centre. Forty-four patients completed the after-sensation protocol. Most patients reported pain after application of less mechanical pressure than HCs; median arm and leg thresholds were 167kPa and 233kPa. Eighty-four percent (31/37) of patients reported ongoing pain at the site of pressure application one day after testing, and 49% (18/37) still perceived pain at five days. After-sensations following brushstroke were common in the FMS group, reported by 77% (34/44) compared to 25% (4/16) of HCs; 34% (15/44) patients, but no HCs, perceived these after-sensations as uncomfortable. For FMS patients who experienced after-sensations, brushstroke-pleasantness ratings were reduced, and skin was often an important site of pain.

Pain after blunt pressure assessment typically lingers for several days. After-sensations following brushstroke stimulation is a previously unreported FMS phenomenon. They are associated with tactile anhedonia and may identify a clinically distinct subgroup.

## Keywords

Fibromyalgia, Chronic pain, Painful after-sensations, PAS, Quantitative sensory testing, QST, Lingering Pain

## Introduction

Fibromyalgia syndrome (FMS) is a chronic widespread pain condition of uncertain aetiology<sup>(1)</sup>. FMS pain, associated tenderness<sup>(1)</sup> and fatigue often have a devastating impact on patients' function, activity, and quality of life<sup>(2, 3)</sup>. FMS has been classically viewed as a pain state with central amplification<sup>(1, 2, 4)</sup>. However, there is also mounting evidence of peripheral abnormalities including small fibre pathology with abnormal nociceptor function<sup>(5-9)</sup> and abnormal thermoregulatory peripheral innervations<sup>(10)</sup>.

In patients with FMS, quantitative sensory testing (QST)<sup>(11, 12)</sup> demonstrates marked hypersensitivity to a broad spectrum of standardised stimuli; such hypersensitivity is established by registering the patient's evaluation of the stimulus while it is applied<sup>(13, 14)</sup>. Patients' blunt pressure pain thresholds are typically reduced, termed static mechanical allodynia<sup>(15)</sup>, but gentle brushstroke may only induce pain, or dynamic mechanical allodynia (DMA), in 10-20%<sup>(16)</sup>. In relation to *noxious thermal* stimuli, (*i.e.*, stimuli that would be painful in normal skin), patients with FMS, similar to patients with other chronic pain conditions, may report painful '*after-sensations*' (PAS), *i.e.*, sensations that persist even though application of the stimulus has ceased<sup>(17-19)</sup>. In FMS, such PAS occur in up to 83% of cases following noxious thermal stimuli (*e.g.*, 49.5°C - 51.5°C), with the remainder of patients experiencing non-painful after-sensations<sup>(20)</sup>. Thermal PAS also occur in healthy individuals, at a frequency of 20% to 37% but, aside from being more common, they are more painful and longer-lasting in FMS<sup>(20-24)</sup>. Following noxious mechanical pressure cuff stimuli, PAS also occur at an increased frequency in FMS, at 50% compared to 12% in controls and are correlated with clinical pain intensity<sup>(25)</sup>.

Anecdotally, other types of skin stimuli may also elicit painful after-sensations in patients with FMS; for example, in our practice, tender point testing required for the 1990 American College of Rheumatology<sup>(26)</sup> (ACR) diagnostic protocol seems to cause long-lasting pain increases at the testing sites. To our knowledge, no quantitative or qualitative data on after-sensations following brushstroke stimuli have been published. Our goal in this study was to describe, in patients with persistent FMS, after-sensations arising from aspects of mechanical QST assessment and from clinical examination as per ACR 1990, and to characterise subgroups formed based on these phenomena. Here, we report on after-sensations following application of both blunt mechanical pressure and brushstroke in a cohort of patients with FMS.

## Methods

### Study design and study subjects

Patients participated in an ongoing phenotyping study aiming to correlate clinical with immunological phenotypes (ISRCTN:18414398). They had been identified from a registry of patients assessed for treatment with an interdisciplinary pain management program (PMP), at a tertiary National Health Service hospital in northern England (The Walton Centre). All patients had consented for their names to be entered into this registry; the consenting rate for entry is 98%.

Patients were approached for the phenotyping study by letter, and interested patients attended for a single study visit. Inclusion criteria were FMS of over one year duration, ACR diagnosis 2010<sup>(3)</sup> or 1990<sup>(26)</sup> (both were assessed on the day and either qualified), age above 18 years, and an average weekly pain intensity of  $\geq 4/10$  on a numerical rating scale (where 0 = 'no pain', and 10 = 'as bad as you can imagine'). The examination for tender points as per ACR 1990<sup>(26)</sup> was conducted after some training had occurred to achieve a pressure of approximately 4kg/cm<sup>2</sup>. Exclusion criteria included pregnancy or breastfeeding and inadequate understanding of the English language.

With regards to after-sensations, drawing from clinical experience, we expected that patients would find both the clinical examination of tender points<sup>(26)</sup> and examination with the pressure algometer (see below) painful for a prolonged period following the assessment, and we wished to study the duration of that response. Patients were given a pain diary to enter the presence or absence of any lingering pain from the examination of ACR 1990 tender points<sup>(26)</sup> and algometry test sites on each of days one to five after their study visit, and these scores were communicated over the telephone after this period.

Upon examination with brushstroke, as part of a protocol to assess pleasant touch, initial patients in this phenotyping study unexpectedly reported post-examination after-sensations, which often seemed unpleasant. These initial research subjects further advised that it was challenging for them to clearly identify after-sensations as 'painful', and that the term 'uncomfortable' would best encompass the unpleasant sensation that they experienced. We consequently adapted the study protocol to allow a more in-depth assessment of this phenomenon. We obtained ethics approval to enquire about the

1  
2  
3 character of these sensations, and to include a pain-free healthy control (HC) comparator group, which  
4 was subsequently recruited from university and healthcare staff.  
5  
6  
7

8  
9 The phenotyping study received ethical approval from Health and Care Research Board Wales:  
10 18/WA/0234. All participants gave written consent, and they were reimbursed expenses up to £30 for  
11 their travel and HCs an additional £30 for their time.  
12  
13  
14

### 15 16 **Study procedure**

17 Following consent and confirmation of eligibility (see above), patients were asked questions pertaining  
18 to their general health and fibromyalgia symptomatology; this included the tissue location of their  
19 perceived most intense pains in either 'bones', 'skin', 'muscles', or 'joints'; with multiple answers  
20 permitted. Participants also self-completed a set of standardised questionnaires which were then  
21 checked for completeness by a member of the team. These included the EQ-5D<sup>(27)</sup>, the McGill Short  
22 Questionnaire<sup>(28)</sup>, a Brief Pain Inventory (BPI)<sup>(29)</sup>, the Hospital Anxiety and Depression Scale (HADS)<sup>(30)</sup>,  
23 the Pain Catastrophizing Score<sup>(31)</sup>, the Experiences in Close Relationship Questionnaire (Revised)  
24 (ECR-R)<sup>(32)</sup>, the Pain Self-Efficacy Questionnaire (PSEQ)<sup>(30)</sup>, the Revised Fibromyalgia Impact  
25 Questionnaire (FIQR)<sup>(33)</sup> and PainDETECT<sup>(33)</sup>. All patients were then examined for their skin sensitivity  
26 (see next section).  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **QST Procedure**

41 A brief mechanical QST protocol was designed to test patients' mechanical pain threshold and skin  
42 sensitivity based on that previously published by Boehme *et al.*<sup>(34)</sup>. The procedure was performed by  
43 RB and AG following training by AM. The tests took place in a quiet, temperature-controlled (21°C) test  
44 room.  
45  
46  
47  
48  
49

### 50 **Pressure pain threshold**

51 Subjects were asked to sit comfortably, and a standardised script read to them (see Supplementary  
52 material, Figure S2). The script read:

53  
54  
55  
56  
57 *"I will press this pressure measuring device against one of your muscles. Please immediately say NOW*  
58 *as soon as the usual sensation of pressure changes to an additional sensation which is painful such as*  
59  
60

1  
2  
3 *'burning', 'stinging', drilling' or 'aching'. This is not an endurance test, tell us as soon as this becomes*  
4 *painful. This will be carried out a total of 3 times."*  
5  
6

7 Static blunt pressure pain threshold was measured using a pressure algometer (FDN200; Wagner  
8 Instruments, Greenwich, CT, USA) with a 1cm<sup>2</sup> rubber tip, which was placed on the skin and a  
9 continuous ramp of increasing intensity (approximately 0.5kg/s, corresponding to 50kPa/s using a  
10 metronome) was applied until the patient confirmed that the sensation of pressure had changed to an  
11 additional one of pain. The patient was not able to see the dial. The pressure pain threshold was  
12 determined by the arithmetic mean of three consecutive readings. The test sites were the lateral right  
13 arm over brachioradialis and the left leg over vastus lateralis.  
14  
15  
16  
17  
18  
19

### 20 **Brushstroke**

21 Keen to explore gentle touch in greater depth than can be achieved by formal QST, which measures  
22 only DMA<sup>(11)</sup>, we chose to focus on slow and fast brushstroke QST, coupling this with the qualitative  
23 perception of skin sensation. This was interrogated using a mixed methods approach<sup>(35)</sup>. Subjects were  
24 asked to sit comfortably with their *left* arm supinated on a pillow. Participants were shown the numerical  
25 scales before brushstroke examination and instructed that they would be stroked with a soft brush. A  
26 30cm ruler was placed securely alongside their arm. The ruler placement marked the test site and was  
27 consistent for all tests. Participants received gentle stroking touch applied manually to the skin of the  
28 lateral left forearm in the supinated position at slow (3cm/s) and fast (30cm/s) speeds from proximal to  
29 distal (with the hair) over a 10cm length. A QST brush (SENSELab Brush-05, Somedic SenseLab  
30 AB Norra Mellby, Sweden) was used to deliver the stimulus and a metronome used to ensure correct  
31 speeds. The brushstroke was not obscured from the participants. Immediately following each  
32 brushstroke, subjects were asked to rate their perceptions on grounded 5cm numerical rating scales  
33 (NRS) for pleasantness, intensity, ticklishness and pain. The anchoring statements are shown in  
34 parenthesis and were as follows. Pleasantness was rated from -5 ('very unpleasant') to +5 ('very  
35 pleasant'). Participants were then asked to rate the intensity on a grounded NRS of 0 ('no sensation')  
36 to 10 ('very intense'). Ticklishness was rated from 0 ('not ticklish') to 10 ('very ticklish'), and pain from 0  
37 ('none) to 10 ('worst possible').  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Following the protocol adaptation from participant eight onwards (see above), subjects were additionally  
56 asked (after completing these NRS descriptions ~ 30 seconds) about the presence of any brushstroke  
57 test sensations that occurred immediately following the cessation of the final stimulus, using a  
58  
59  
60

1  
2  
3 combination of yes/no, multiple-choice and open-ended questions<sup>(35)</sup>. Firstly, the subjects were asked:  
4 'After the brushstroke tests, have you felt any lingering sensation?' ('yes or no'). If the subjects  
5 confirmed the presence of such lingering sensations, they were asked to describe their quality; 'did this  
6 lingering sensation feel like 'pins and needles', 'burning' or 'other'. Subjects were encouraged to report  
7 in free text all they felt and were permitted to select or record multiple types of sensations, as relevant.  
8  
9 Subjects were then asked whether their sensations following brushstroke were uncomfortable ('yes' or  
10 'no'). We have termed sensations extending beyond the brushstroke tests as 'after-sensations'. For  
11 testing protocols, please see supplementary material, Figure S2.  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Statistics**

21  
22 Data were collated using Microsoft Excel version 16 (Microsoft Corporation, Redmond, WA, USA) and  
23 analysed with GraphPad Prism version 9 (GraphPad Software Inc., San Diego, CA, USA). Normality of  
24 data were tested with the Kolmogorov-Smirnov test. For normally distributed data, a paired or unpaired  
25 Students T test with Welch's correction for unequal variance was used. For non-normally distributed  
26 data, a Wilcoxon matched pairs rank sum test was used for paired data, and a Mann-Whitney test for  
27 unpaired data. For comparison of multiple non-normally distributed groups a Kruskal-Wallis test was  
28 implemented. For categorical binary data a Fisher's exact test was used. For the non-normally  
29 distributed brushstroke tests and pressure pain threshold data a Kruskal-Wallis test was utilised with a  
30 Dunn's post hoc test between groups with correction for multiple comparisons. A multiple linear  
31 regression model using a least squares approach was used to analyse variability in brushstroke  
32 pleasantness, modelling for intercept and main effects only, and residual plots assessed for assumption  
33 validity. Correlation was tested with a Pearson's correlation coefficient and, again, residual plots  
34 assessed. Odds ratios were calculated for the probability of experiencing after-sensations with FMS.  
35  
36 Statistical significance was set at  $p < 0.05$ , and a correction for multiple comparisons was made for each  
37 hypothesis (*e.g.*, Bonferroni). All  $p$  values under 0.05 were displayed for completeness. We speculated  
38 that some aspects of the FIQR were particularly relevant in testing the hypothesis that after-sensations  
39 had clinical relevance and, therefore, analysed several FIQR sub-items individually which ranged from  
40 0 (least) to 10 (maximal impact) (Supplementary Table S2).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### 1. Demographics

Demographic data is displayed in Table 1 for all 51 patients and 16 healthy controls (HC). In the FMS group, there were 46 females with a mean age of 49.4 years (26 to 66) and five males with a mean age of 41.6 years (24 to 58). Prior to recruitment, 32/51 patients had completed a comprehensive, 16 day (>100 hours) interdisciplinary PMP, whereas 19 patients had been assessed for the program but were not treated. FMS patients were noted to have a higher weight and BMI than HCs. Patients had a mean symptom duration of 10.6 years, and both their resting pain and seven-day average pain rating was 7/10. The average HADs scores for anxiety and depression were both 11.7, which is at the clinical threshold for anxiety and depression. The mean PCS, EQ-VAS, and FIQR scores were 24.3, 46.6 and 69.9, respectively. Chronic pain preceding widespread pain was common at 80% (41/51).

#### [Table 1]

### 2. FMS patients are more sensitive to mechanical stimuli than HCs and perceive less pleasure from gentle touch (tactile anhedonia)

Figure 1 displays data from the pressure pain thresholds and the brushstroke tests. As expected, the median pressure pain threshold values were significantly reduced in the FMS patients at both the right arm and left leg (Figure 1a). Brushstroke intensity (NRS) was not significantly different between FMS and HC cohorts for either slow or fast brushstrokes (Figure 1b). FMS patients reported both slow and fast brushstrokes as significantly less pleasant (Figure 1c). Within the HC cohort, slow brushstrokes were not more pleasant than fast with our multiple variable analysis (Kruskal-Wallis with Dunn's post hoc test) which is contrary to reported findings<sup>(34)</sup>. We chose, also, to analyse our data as done in previous studies which have assessed slow and fast brushstrokes QST, in which data were dichotomized by slow or fast brushstroke and tested using a Mann Whitney U test. In this analysis our data recapitulates the observation previously found ( $p < 0.01$ )<sup>(34)</sup>. In our multiple variable analysis we found a trend towards reduced ticklishness of brushstrokes in the FMS group, which did not reach significance (Figure 1d). Brushstrokes were rarely painful (i.e., there was little dynamic-mechanical allodynia); the median pain intensity during these strokes was zero in both study groups for both slow and fast (Figure 1e). In total 14% (7/51) of FMS subjects reported pain scoring between 0.0 and 4.3/10

1  
2  
3 for slow brushstrokes and between 0.0 and 3.3/10 for fast brushstrokes. No HCs reported pain.  
4  
5 Considering the small number of patients experiencing dynamic mechanical allodynia (n=7), there was  
6  
7 no trend regarding this parameter and the perceived anatomical the location of worst pain.  
8  
9

10  
11 It is conceivable that PMP treatment might alter patients' affective experiences as a result of the  
12  
13 psychological interventions provided as part of the program. Subgroup analysis showed that the slow  
14  
15 stroke intensity, slow stroke pain, fast stroke intensity and fast stroke pain were significantly less in  
16  
17 patients who had previously been treated with this intervention, however, following p value correction  
18  
19 for multiple tests, only slow stroke intensity remained significantly reduced. Interestingly, the  
20  
21 brushstroke pleasantness ratings were not affected (Supplementary Figure S3).  
22  
23  
24  
25

26  
27 **[Figure 1]**  
28  
29  
30  
31

32 **3. Brushstroke pleasantness is negatively correlated with PainDETECT values but not WPI,**  
33 **SSS, PCS or HADS.**  
34  
35

36  
37 **[Figure 2]**  
38  
39

40 We identified a fair degree of variability in the pleasantness ratings in the FMS group. To test for  
41  
42 associations which might explain the loss of pleasant touch, we performed a multiple regression  
43  
44 analysis with a model considering the degrees of pain-widespreadness and somatic symptoms (WPI,  
45  
46 SSS), psychological factors (PCS, HADs A and HADs D), and neuropathic symptoms as measured by  
47  
48 PainDETECT, assuming a least squares model. Only PainDETECT values (with higher values  
49  
50 indicating more likely neuropathic pain) were significantly (inversely) associated with both slow stroke  
51  
52 pleasantness ( $p < 0.01$ ) and fast stroke pleasantness ( $p < 0.0001$ ) (Figure 2). For slow brushstroke  
53  
54 pleasantness, Pearson's correlation coefficient ( $r$ ) was 0.3951 (95% CI: -0.6405 to -0.0765;  $p < 0.05$ ),  
55  
56 and for the fast brushstroke  $r$  was -0.4866 (95% CI: -0.7028 to -0.1881;  $p < 0.005$ ).  
57

58 **4. After-sensations**  
59  
60

1  
2  
3 Patients reported lingering pain at the examination sites (tender-point or pressure algometry) with a  
4 frequency of 78.1% (25/31) at day one and 46.7% (14/30) at day five. *Brushstroke after-sensations*  
5 were experienced by 77.3% (34/44) FMS subjects (Figure 3a). In almost half (15/34) of these patients  
6 (15/44 of all tested FMS patients), the reported sensation was classed as 'uncomfortable'. At a 25%  
7 (4/10) incidence, HCs experienced after-sensations with a significantly diminished frequency  
8 ( $p < 0.0005$ ), which were never uncomfortable. The odds ratio of experiencing after-sensations with FMS  
9 was 10.2 (95% CI: 2.5 - 32.4). When considering only patients that experienced dynamic mechanical  
10 allodynia, 83.3% (5/6) had after-sensations and in 66.8% (4/6) these were uncomfortable.

### 11 [Figure 3]

12 The qualities of these after-sensations were similar in FMS patients between uncomfortable after-  
13 sensations (UAS) and not-uncomfortable after-sensations (nUAS), with 'pins and needles' being the  
14 modal response, followed by a lingering sensation that the brushstroke was still taking place (Figure  
15 3b). The median number of reported sensations was one, ranging from one to three. For HCs the after-  
16 sensations were 'cool' (1/4) 'brush still there' (1/4) or 'tingling' (2/4).

17 When stratifying patients by whether they had undergone the PMP treatment, no trend was seen in the  
18 presence of brushstroke after-sensations. Of the 25 patients that attended the PMP, 76% (19/25) had  
19 after-sensations, and of the 19 that did not attend the PMP, 79% (15/19) had after-sensations.

## 20 5. Patient phenotypes by brushstroke after-sensations

21 We compared demographics and FMS characteristics between patients with and without brushstroke  
22 after-sensations to examine whether this characteristic was associated with a particular clinical  
23 phenotype. We found that these groups did not differ in gender, age, FIQR, level of pain, WPI or SSS,  
24 pain catastrophising or EQ-VAS (Table 2).

25 Patients were asked about the perceived tissue location of their most intense pains as either 'bones',  
26 'skin', 'muscles', or 'joints', with multiple responses permitted. Eleven patients (out of  $n=44$  who  
27 completed this question) recorded 'skin' as site of their most intense pain, and those with UAS reported  
28 'skin' more often (47%, 7/15) when compared to nUAS (20%, 2/10) or nAS groups (2/19, 11%;  $p < 0.05$ ;  
29 Supplementary Figure S1).

1  
2  
3 Those patients who experienced after-sensations rated fast brushstrokes significantly more unpleasant  
4 than the other groups (Table 2). Subgroup analyses across the three groups UAS, nUAS and nAS  
5 (Supplementary Table S1), indicated slow and fast brushstroke pleasantness measures to be  
6 significantly different, with the UAS group rating brushstrokes least pleasant compared to the other  
7 groups.  
8  
9  
10  
11

12  
13 Should patients indeed perceive uncomfortable sensations following gentle stroking of their skin, this  
14 may well have deleterious manifestations relevant to their everyday life, such as social interaction within  
15 the family. We compared, therefore, the UAS, nUAS and nAS groups with respect to the relevant FIQR  
16 sub-items (Supplementary Table S2). No association was found with pertinent individual FIQR  
17 measures, e.g., on combing hair, sleep quality or overall pain, although there appeared to be a trend  
18 for the parameter 'sensitivity to touch',  
19  
20  
21  
22  
23

24 [Table 2]  
25  
26  
27

## 28 Discussion

29  
30 In this study we have investigated after-sensations persisting beyond the termination of mechanical  
31 stimuli applied to FMS patients' skin. We found that painful 'after-sensations' (lingering pains) are  
32 frequently reported several days after study examination, which included application of blunt pressure  
33 during the ACR tender point examination (approximately 4kg/cm<sup>2</sup>), pressure pain threshold testing and  
34 brushstroke QST. Eighty percent (25/31) of patients had lingering pain on day one and 47% (14/30) on  
35 day five after examination. The existence of this phenomenon following *blunt mechanical* stimuli has  
36 previously been highlighted by others<sup>(20)</sup> and has often been communicated by patients in our own  
37 clinical practice, however, to our knowledge our data provide a first account of its prevalence and  
38 duration. The pressure required to generate a noxious stimulus in HCs is typically (200 – 300kpa for  
39 the arm and 250 – 450kpa for the leg)<sup>(36)</sup>. FMS pressure measurements observed in this study are lower  
40 than these, representing mechanical hyperalgesia.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 This finding also confirms that tender point examination in FMS can regularly cause long-lasting  
53 discomfort. A count of painful tender points was part of the now superseded ACR 1990 diagnostic  
54 criteria<sup>(26)</sup>. Although the current diagnostic criteria (ACR 2016)<sup>(37)</sup> do not include a count of painful tender  
55 points, the 1990 criteria are still in wide use, and our results may support diagnosticians in choosing a  
56 different appropriate set of diagnostic criteria. These data also support clinical advice to minimise repeat  
57  
58  
59  
60

1  
2  
3 examination in FMS patients in all settings<sup>(38)</sup>, and our recommendation that patients should be  
4 consented to expect increased pain from an examination.  
5  
6

7  
8 To our knowledge, this is the first report of evoked paraesthesia or, 'after-sensations' following skin-  
9 brushstroke testing in FMS. We found that such sensations are common compared with HCs and that  
10 patients, but not HCs, often perceive them as uncomfortable. Consistent with the literature, allodynia,  
11 defined as pain *during* brushstroke application, was reported by some of our patients (7/51)<sup>(36)</sup>. This  
12 phenomenon in health, however, is not expected to continue after stimulus withdrawal.  
13  
14

15  
16 Within the FMS group, *reports of uncomfortable, as opposed to non-uncomfortable or no after-*  
17 *sensations, following brushstroke were associated with reports of reduced pleasantness during*  
18 *brushstroke; on average slow and fast brushstrokes were, in fact, perceived as unpleasant* by this  
19 group. Experience of uncomfortable brushstroke after-sensations was not associated with blunt  
20 pressure sensitivity, however, (Supplementary Table S1) and it was particularly frequent in those  
21 patients who noted that their skin was the location of their worst pain (Supplementary Figure S1) These  
22 features may, therefore, characterise a distinct FMS clinical subgroup in which touch processing is  
23 differentially affected.  
24  
25

26  
27 Reduced brushstroke pleasantness (*i.e., during the brushstroke*) – termed anhedonia, as detected in  
28 our study, is consistent with recent reports by Boehme *et al.*<sup>(34)</sup> and others, although its cause is still  
29 unclear<sup>(39, 40)</sup>. By mapping cortical activity during brush stroking with functional magnetic resonance  
30 imaging, Boehme *et al.* found an inverted pattern of insula activity compared to HCs and inferred,  
31 therefore, that FMS anhedonia may be related to aberrant central nervous system evaluative  
32 processing<sup>(34)</sup>. Nonetheless, the finding of anhedonia in FMS does not exclude the possibility of  
33 abnormal signal processing of input from sensory afferents. Certainly, evidence of small fibre pathology  
34 in FMS is mounting<sup>(41, 42)</sup> with reports of reduced epidermal nerve fibre density<sup>(40)</sup> and reduced vascular  
35 innervation<sup>(43)</sup>. Bosma *et al.* show that *painful* after-sensations after thermal stimuli are associated with  
36 increased activation in the cervical cord dorsal horn in FMS patients<sup>(23)</sup>, pointing, perhaps to continued  
37 afferent activity.  
38  
39

40  
41 The inverse correlation of brushstroke pleasantness in our FMS cohort with the PainDETECT score  
42 may further signal small fibre pathology as one mechanism of anhedonia in FMS. Should the former be  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 true, and brushstroke testing predict small fibre pathology, then using brushstroke testing to diagnose  
4 small fibre pathology would be much preferable to a painful skin biopsy<sup>(41)</sup>. In summary, anhedonia  
5 could be a consequence of abnormal afferent input, altered spinal processing or altered brain  
6 processing.  
7  
8  
9

10  
11  
12 It is, tempting to speculate that at least the 'early' (i.e., ~15 seconds<sup>20</sup>) brushstroke after-sensations  
13 may be mediated by slowly conducting C fibres. One such candidate is the CT fibre, a low threshold  
14 afferent which discharges maximally with a slow (1–10 cm/s) brushstroke and elicits a pleasant  
15 sensation in subjects<sup>(44)</sup>. These CT fibres, which are suited to respond to a 'gentle caress', are thought  
16 to provide the 'neurobiological substrate for the affective and rewarding' aspects of touch<sup>(45)</sup>. This 'social'  
17 touch is clearly important for physical and social wellbeing<sup>(45)</sup> and its loss, tactile anhedonia, is a clear  
18 feature of FMS<sup>(34)</sup>. Because CT fibres fire preferentially after stimuli with brushstroke speeds of 1-10  
19 cm/s, one might expect after-sensations to be more strongly associated with slow rather than fast  
20 brushstroke pleasantness. However, we note that this would suppose that CT firing is normal in FMS –  
21 an assumption that has yet to be confirmed. CT afferent firing in health has a propensity to exhibit after-  
22 discharges upon cessation of an innocuous tactile stimulus<sup>(9)</sup> which further points to a potential role in  
23 the development of after-sensations. A further way to investigate this would be a comparison between  
24 brushstrokes and vibro-tactile stimuli, the latter of which strongly activate A-fibre low threshold  
25 mechanoreceptor afferents but only weakly excite CT afferents<sup>(9, 45)</sup>. However, it is important to note  
26 that brush stroking will activate A-beta and A-delta fibres, as well as the CT afferents, which may all  
27 integrate centrally. There are, of course, other explanations, such as reverberating circuits in the CNS  
28 or the aforementioned after-discharging afferents.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Intriguingly, patients that had attended our PMP treatment had reduced slow brushstroke intensity  
48 ratings. Brushstroke pleasantness ratings were not altered, however. This data might provide the first  
49 evidence of PMP treatment potentially affecting selected sensory characteristics in FMS. However,  
50 given that all patients in this study had been assessed for the suitability of PMP treatment, it is  
51 alternatively possible that the entrance criteria for our PMP also selected for patients with a distinct  
52 sensory phenotype. A prospective study in PMP participants would shed more light on these issues.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Dynamic mechanical allodynia and dysesthesias are noted in several neuropathic pain conditions (e.g.,  
4 post herpetic neuralgia pain)<sup>(46)</sup> as well as fibromyalgia<sup>(16)</sup>. We note that DMA was also present in our  
5 study at a 10% incidence. The cohort of patients with after-sensations also had a higher incidence of  
6  
7 DMA.  
8  
9

10  
11 The PainDETECT questionnaire was validated as a tool to predict the relative contribution of  
12 neuropathic pain in neuropathic and nociceptive (e.g., osteoarthritis) conditions. Fibromyalgia patients  
13 were excluded from the validation process, although PainDETECT has been increasingly used in this  
14 population. It has been proposed that fibromyalgia should not be considered as a neuropathic pain  
15 state<sup>(47)</sup>, however, with mounting evidence that FMS has a peripheral component<sup>(5-9)</sup> it is, perhaps,  
16 unsurprising that fibromyalgia patients experience similar sensory phenomena as patients suffering  
17 from neuropathic conditions<sup>(47)</sup>. In this study, it is curious that although tactile anhedonia is associated  
18 with the PainDETECT score, pain intensity, fibromyalgia severity (FIQR), measures of  
19 “widespreadness” (WPI, SSS) or cognitive qualities, such as pain catastrophising, are not.  
20  
21 Regardless of the underlying mechanism, be this neuropathy or something else, it seems plausible that  
22 tactile anhedonia points to a distinct phenotype.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 The German Research Network on Neuropathic Pain (DFNS)<sup>(11)</sup> has generated a robust and  
35 reproducible QST protocol for assessing patients with neuropathic pain. Whilst a thorough, useful, and  
36 widely accepted approach, the experimental protocol does not account for the assessment of  
37 sensations that linger following stimulus withdrawal. We suggest, therefore, that the DFNS protocol may  
38 have been failing to capture a common and germane clinical sequela of chronic pain.  
39  
40  
41  
42  
43  
44

45 Our present study is limited as it was not designed to interrogate after-sensations in detail, which were  
46 a surprise finding. We did not record their duration nor examine whether their qualities were the same  
47 for both slow and fast brushstrokes. It should be noted that we did record a significant reduction in  
48 pleasantness between slow and fast brushstrokes in HC and not in FMS, which has been previously  
49 noted and underpins the C-fibre tactile theory, although it failed to meet significance in our study in all  
50 analyses. The control group was small and was restricted to females, and it did not, therefore, match  
51 the FMS group in this regard. Although the proportion of male FMS patients included was small (n=3)  
52 it is conceivable that after-sensations had some gender bias: in our FMS cohort, all males on which we  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 have data, had after-sensations. The HC group also differed by age, BMI, and weight which were  
4 potential confounders.  
5

6  
7 It is important to note that in this present study we measured both brushstroke QST and pressure  
8 algometry, and we performed tender point examination. It is not possible, therefore, to extract the  
9 relevant contributions of each of these in relation to persisting after-sensations (lingering pain). We  
10 further note that the pressure algometry, unlike the tender point examination stopped exactly at the  
11 point of painfulness and involved two points on the body (the tender point examination involved 18  
12 points), therefore, we assume that the tender point examination was responsible for most of the  
13 lingering pain, however, this study was not designed to confirm this.  
14  
15

16  
17 We did not record data on the presence or absence of after-sensations in the HC group following  
18 pressure pain threshold detection and this is a clear limitation. HCs have been reported to experience  
19 painful after-sensations following blunt pressure mechanical stimulus, though the frequency was low at  
20 12% and of an unknown duration<sup>(25)</sup>. FMS patients are probably heterogenous in sensory phenotypes<sup>(48)</sup>  
21 and it is true that such variability would hamper our ability to distinguish between groups. As an  
22 exploratory study, we were not powered to tease out subtle relationships between after-sensations and  
23 psychometric data. A larger study is warranted for this. Our cohort was obtained from a tertiary referral  
24 centre and may not, therefore, have been fully representative of all patients in the community. Albeit,  
25 using this pilot data, it would now be possible to adequately power a study to test the hypothesis that  
26 the uncomfortable after-sensation group is more sensitive (as suggested by the association with  
27 reduced brushstroke pleasantness), possibly with respect to social measures, such as assessed by  
28 TEAQ<sup>(49)</sup>. In addition to these measures, biochemical changes might also be investigated, for example  
29 cortisone or endorphin levels locally or systemically. We placed emphasis on the bothersome-ness of  
30 patient symptomatology and, in this regard, further work might look to investigate the presence and  
31 character of itch and how this is related to ticklishness. Examinations for atypical allodynia and  
32 paraesthesia can easily be done in the clinical setting and understanding patient phenotypes in terms  
33 of these may be clinically useful, therefore.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **Conclusion**

55  
56 Here we report, for the first time, the presence of after-sensations following the cessation of an  
57 innocuous light touch stimulus in a cohort of fibromyalgia patients. When present, these after-  
58  
59  
60

1  
2  
3 sensations are often uncomfortable. We also report on the prevalence of lingering pain following  
4 pressure examination. We suggest that these findings have key implications for clinicians examining  
5 patients and ramifications for experimental trajectories. Their recognition may provide assuage to  
6 patients and inform the advice and education given. Further research is, of course, needed to  
7 investigate these phenomena in FMS and other chronic pains. In this regard, we note that medical  
8 efficacy is contingent upon placing patients at the centre of diagnostic formulations and the interrogation  
9 of aetiologies.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 This research has been supported by grants from MRC (MR/S003428/1) to A.G & D.A. and the Pain  
23 Relief Foundation (A.G. & R.B.) The authors have no conflicts of interest to disclose.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Sluka K, Clauw D. Neurobiology of fibromyalgia and chronic widespread pain. *Neuroscience* 2016;**338**: 114-29.
2. Clauw DJ. Fibromyalgia: an overview. *Am J Med* 2009;**122**(12 Suppl): S3-S13.
3. Wolfe F, Clauw D, Fitzcharles M, Goldenberg D, Katz R, Mease P, Russell A, Russell I, Winfield J, Yunus M. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. *Arthritis Care & Research* 2010;**62**(5): 600-10.
4. Clauw D. Fibromyalgia A Clinical Review. *Jama-Journal of the American Medical Association* 2014;**311**(15): 1547-55.
5. Serra J, Collado A, Sola R, Antonelli F, Torres X, Salgueiro M, Quiles C, Bostock H. Hyperexcitable C nociceptors in fibromyalgia. *Annals of Neurology* 2014;**75**(2): 196-208.
6. Lawson V, Grewal J, Hackshaw K, Mongiovi P, Stino A. Fibromyalgia syndrome and small fiber, early or mild sensory polyneuropathy. *Muscle & Nerve* 2018;**58**(5): 625-30.
7. Grayston R, Czanner G, Elhadd K, Goebel A, Frank B, Üçeyler N, Malik RA, Alam U. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. *Semin Arthritis Rheum* 2019;**48**(5): 933-40.
8. Evdokimov D, Dinkel P, Frank J, Sommer C, Uceyler N. Characterization of dermal skin innervation in fibromyalgia syndrome. *PLoS One* 2020;**15**(1): e0227674.
9. Goebel A, Krock E, Gentry C, Israel MR, Jurczak A, Urbina CM, Sandor K, Vastani N, Maurer M, Cuhadar U, Sensi S, Nomura Y, Menezes J, Baharpoor A, Brieskorn L, Sandstrom A, Tour J, Kadetoff D, Haglund L, Kosek E, Bevan S, Svensson CI, Andersson DA. Passive transfer of fibromyalgia symptoms from patients to mice. *J Clin Invest* 2021;**131**(13).
10. Albrecht PJ, Hou Q, Argoff CE, Storey JR, Wymer JP, Rice FL. Excessive peptidergic sensory innervation of cutaneous arteriole-venule shunts (AVS) in the palmar glabrous skin of fibromyalgia patients: implications for widespread deep tissue pain and fatigue. *Pain Med* 2013;**14**(6): 895-915.
11. Rolke R, Baron R, Maier C, Tolle T, Treede R, Beyer A, Binder A, Birbaumer N, Birklein F, Botefur I, Braune S, Flor H, Hüge V, Klug R, Landwehrmeyer G, Magerl W, Maihofner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. *Pain* 2006;**123**(3): 231-43.
12. Arendt-Nielsen L, Yarnitsky D. Experimental and Clinical Applications of Quantitative Sensory Testing Applied to Skin, Muscles and Viscera. *Journal of Pain* 2009;**10**(6): 556-72.
13. Berglund B, Harju EL, Kosek E, Lindblom U. Quantitative and qualitative perceptual analysis of cold dysesthesia and hyperalgesia in fibromyalgia. *Pain* 2002;**96**(1-2): 177-87.
14. Berwick RJ, Siew S, Andersson DA, Marshall A, Goebel A. A Systematic Review Into the Influence of Temperature on Fibromyalgia Pain: Meteorological Studies and Quantitative Sensory Testing. *J Pain* 2021;**22**: 473-86.
15. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. *Pain* 2003;**105**(3): 403-13.

- 1  
2  
3 16. Oudejans L, He X, Niesters M, Dahan A, Brines M, van Velzen M. Cornea nerve fiber quantification and  
4 construction of phenotypes in patients with fibromyalgia. *Scientific Reports* 2016;**6**: 23573.  
5  
6  
7 17. Anderson RJ, McCrae CS, Staud R, Berry RB, Robinson ME. Predictors of clinical pain in fibromyalgia:  
8 examining the role of sleep. *J Pain* 2012;**13**(4): 350-8.  
9  
10 18. Sato H, Saisu H, Muraoka W, Nakagawa T, Svensson P, Wajima K. Lack of Temporal Summation but Distinct  
11 Aftersensations to Thermal Stimulation in Patients with Combined Tension-Type Headache and Myofascial  
12 Temporomandibular Disorder. *Journal of Orofacial Pain* 2012;**26**(4): 288-95.  
13  
14 19. Staud R, Weyl EE, Riley JL, 3rd, Fillingim RB. Slow temporal summation of pain for assessment of central pain  
15 sensitivity and clinical pain of fibromyalgia patients. *PLoS One* 2014;**9**(2): e89086.  
16  
17 20. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of  
18 second pain (wind-up) in patients with fibromyalgia syndrome. *Pain* 2001;**91**(1-2): 165-75.  
19  
20 21. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second  
21 pain and its central modulation in fibromyalgia patients. *Pain* 2002;**99**(1-2): 49-59.  
22  
23 22. Staud R, Price DD, Robinson ME, Vierck CJ, Jr. Body pain area and pain-related negative affect predict clinical  
24 pain intensity in patients with fibromyalgia. *J Pain* 2004;**5**(6): 338-43.  
25  
26 23. Bosma RL, Mojarad EA, Leung L, Pukall C, Staud R, Stroman PW. FMRI of spinal and supra-spinal correlates  
27 of temporal pain summation in fibromyalgia patients. *Hum Brain Mapp* 2016;**37**(4): 1349-60.  
28  
29 24. Gottrup H, Kristensen AD, Bach FW, Jensen TS. Aftersensations in experimental and clinical hypersensitivity.  
30 *Pain* 2003;**103**(1-2): 57-64.  
31  
32 25. Schreiber KL, Loggia ML, Kim J, Cahalan CM, Napadow V, Edwards RR. Painful After-Sensations in  
33 Fibromyalgia are Linked to Catastrophizing and Differences in Brain Response in the Medial Temporal Lobe. *J Pain*  
34 2017;**18**(7): 855-67.  
35  
36 26. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles  
37 M, Clark P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the  
38 Multicenter Criteria Committee. *Arthritis Rheum* 1990;**33**(2): 160-72.  
39  
40 27. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonnel G, Badia X. Development and preliminary  
41 testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**(10): 1727-36.  
42  
43 28. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke  
44 LB, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA, Melzack R. Development and initial validation of an expanded  
45 and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). *Pain* 2009;**144**(1-2): 35-42.  
46  
47 29. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant  
48 pain. *J Pain* 2004;**5**(2): 133-7.  
49  
50 30. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;**67**(6): 361-70.  
51  
52 31. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. *Psychological*  
53 *Assessment* 1995;**7**(4): 524-32.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 32. Fraley RC, Waller NG, Brennan KA. An item response theory analysis of self-report measures of adult attachment. *J Pers Soc Psychol* 2000;**78**(2): 350-65.
- 4  
5  
6  
7 33. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. *Arthritis Res Ther* 2009;**11**(4): R120.
- 8  
9  
10 34. Boehme R, van Ettinger-Veenstra H, Olausson H, Gerdle B, Nagi SS. Anhedonia to Gentle Touch in Fibromyalgia: Normal Sensory Processing but Abnormal Evaluation. *Brain Sci* 2020;**10**(5).
- 11  
12  
13 35. Bordeleau M, Leonard G, Gauthier L, Ferland CE, Backonja M, Vollert J, Marchand S, Jackson P, Cantin L, Prud'Homme M. Classification of Qualitative Fieldnotes Collected During Quantitative Sensory Testing: A Step Towards the Development of a New Mixed Methods Approach in Pain Research. *J Pain Res* 2021;**14**: 2501-11.
- 14  
15  
16  
17 36. Melia M, Schmidt M, Geissler B, Konig J, Krahn U, Ottersbach HJ, Letzel S, Muttray A. Measuring mechanical pain: the refinement and standardization of pressure pain threshold measurements. *Behav Res Methods* 2015;**47**(1): 216-27.
- 18  
19  
20  
21 37. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Seminars in Arthritis & Rheumatism* 2016;**46**(3): 319-29.
- 22  
23  
24  
25 38. Royal College of Physicians. The diagnosis of fibromyalgia syndrome. UK clinical guidelines. London: RCP, 2022.
- 26  
27  
28  
29 39. Case LK, Ceko M, Gracely JL, Richards EA, Olausson H, Bushnell MC. Touch Perception Altered by Chronic Pain and by Opioid Blockade. *eNeuro* 2016;**3**(1).
- 30  
31  
32  
33 40. Evdokimov D, Frank J, Klitsch A, Unterecker S, Warrings B, Serra J, Papagianni A, Saffer N, zu Altschiltschesche CM, Kampik D, Malik RA, Sommer C, Uceyler N. Reduction of skin innervation is associated with a severe fibromyalgia phenotype. *Annals of Neurology* 2019;**86**(4): 504-16.
- 34  
35  
36  
37 41. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. *Pain* 2013;**154**(11): 2310-6.
- 38  
39  
40  
41 42. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, Schmid A, Casanova-Molla J, Reiners K, Sommer C. Small fibre pathology in patients with fibromyalgia syndrome. *Brain* 2013;**136**(6): 1857-67.
- 42  
43  
44  
45 43. Evdokimov D, Dinkel P, Frank J, Sommer C, Uceyler N. Characterization of dermal skin innervation in fibromyalgia syndrome. *PLoS One* 2020;**15**(1): e0227674-e74.
- 46  
47  
48  
49 44. Loken LS, Wessberg J, Morrison I, McGlone F, Olausson H. Coding of pleasant touch by unmyelinated afferents in humans. *Nat Neurosci* 2009;**12**(5): 547-8.
- 50  
51  
52  
53 45. McGlone F, Wessberg J, Olausson H. Discriminative and affective touch: sensing and feeling. *Neuron* 2014;**82**(4): 737-55.
- 54  
55  
56  
57 46. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. *Lancet Neurol* 2014;**13**(9): 924-35.
- 58  
59  
60

- 1  
2  
3 47. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tolle TR, Baron R. Fibromyalgia and neuropathic  
4 pain--differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia.  
5 *BMC Neurol* 2011;**11**: 55.  
6  
7  
8 48. Ten Brink AF, Goebel A, Berwick R, McCabe CS, Bultitude JH. Sensitivity to Ambient Temperature Increases  
9 in Fibromyalgia and CRPS. *Pain Med* 2020;**21**(12): 3726–29.  
10  
11 49. Trotter PD, McGlone F, Reniers R, Deakin JFW. Construction and Validation of the Touch Experiences and  
12 Attitudes Questionnaire (TEAQ): A Self-report Measure to Determine Attitudes Toward and Experiences of Positive  
13 Touch. *J Nonverbal Behav* 2018;**42**(4): 379–416.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Legends

### Figure 1: Quantitative Sensory Testing Results

Boxplots display medians, quartiles, and ranges; (a) pressure pain threshold and (b-e) tactile quantitative sensory testing. Abbreviations: SS = slow brushstroke; FS = fast brushstroke; RA = right arm; LL = left leg. For brushstroke tests, statistical significance tested with Kruskal-Wallis with a Dunn's post hoc test corrected for multiple analyses. \*\*\*\*  $p < 0.0001$ ; \*\*\*  $p < 0.001$ ; \*\*  $p < 0.01$ ; \*  $p < 0.05$ ; n.s. not significant.

### Figure 2 – Scatter Plots of Brushstroke Pleasantness Against PainDETECT Scores

Linear regression lines for average slow brushstroke in red for slow brushstroke and in blue for fast. Correlation was tested with Pearson's correlation coefficient. Significance stated pertains to the test for a non-zero slope of the linear regression line. Significance was set at  $p < 0.05$ .

### Figure 3 – After-sensations Following Brushstroke

(a) Percentages of subjects reporting sensations at the site of brushstrokes, following application of a series of 6 brushstrokes (3 slow and 3 fast) delivered in an alternating order to the left arm, are shown as a pie chart. Abbreviations: nAS = no after-sensations; nUAS = non-uncomfortable after-sensations; UAS = uncomfortable after-sensations. (b) The character of the after-sensations; patients were able to report any number of sensations. The  $p$  value pertains to a Fisher's exact test for the presence of after-sensations between HC and FMS. Significance was set at  $p < 0.05$ .

	Healthy pain free subjects <i>n</i> = 16		Fibromyalgia <i>n</i> = 51		
	Mean	95% CI	Mean	95% CI	
<b>Females %</b>	100%		90%		n.s.
<b>Age</b>	41.2	35.6 - 46.8	48.7	45.7 - 51.6	<0.05
<b>BMI</b>	25.9 [15]	22.9 - 28.9	33.5 [43]	31.1 - 35.9	<0.01
<b>Height</b>	1.64 [15]	1.61 - 1.67	1.65 [47]	1.62 - 1.67	ns.
<b>Weight</b>	69.3 [15]	62.3 - 76.3	90.0 [47]	83.5 - 96.5	<0.01
<b>Symptom duration (years)</b>	-	-	10.6	8.9 - 12.3	-
<b>Current Resting Pain</b>	-	-	7.0	6.5 - 7.6	-
<b>Pain in last 7 days</b>	-	-	7.3	6.8 - 7.8	-
<b>HADs Anxiety</b>	-	-	11.7	10.4 - 12.9	-
<b>HADs Depression</b>	-	-	11.7	10.6 - 12.9	-
<b>PCS</b>	-	-	24.3	20.5 - 28.1	-
<b>EQ-VAS</b>	-	-	46.9	41.7 - 52.0	-
<b>FIQR</b>	-	-	69.9	65.6 - 74.2	-

**Table 1 – Demographics of healthy controls and patients and FMS disease characteristics**


Values displayed as means with 95% confidence intervals. Where group size varied this is displayed in square brackets. Abbreviations: PCS = Pain catastrophising scale rating; EQ-VAS - EuroQual visual analogue scale; FIQR = Fibromyalgia impact questionnaire revised. Statistical significance tested with a Mann Whitney U test. Uncorrected *p* value set at 0.05, following Bonferroni correction *p*<0.01, n.s., not significant.

	Brushstroke After-sensations (AS)	No Brushstroke After-sensations (nAS)	
<b>Group size</b>	n = 34	n = 10	
<b>Females (%)</b>	91.2	100.0	n.s.
<b>Age (years)</b>	46.7 (42.3– 50.6)	49.1 (44.5 – 53.7)	n.s.
<b>BMI (kg/m<sup>2</sup>)</b>	33.3 (30.1 – 36.4) [31]	38.2 (35.1 – 41.3)	p<0.05
<b>Duration (years)</b>	10.3 (8.5 – 12.1)	12.5 (6.5 - 18.5)	n.s.
<b>FIQR Total</b>	71.3 (66.0 – 76.6)	66.6 (54.4 – 78.9)	n.s.
<b>FIQR Level of Pain</b>	7.8 (7.2 – 8.4)	7.9 (7.1 – 8.7)	n.s.
<b>WPI</b>	13.1 (12.1 – 14.1)	15.0 (12.5 – 17.5)	n.s.
<b>SSS</b>	10.1 (9.5 – 10.7)	9.5 (8.1 – 10.8)	n.s.
<b>Slow stroke pleasantness (NRS)</b>	0.2 (-0.5 – 0.9)	1.3 (0.1 – 2.6)	n.s.
<b>Fast stroke pleasantness (NRS)</b>	0.0 (-0.5 – 0.5)	1.1 (-0.1 – 2.2)	p<0.05
<b>Slow stroke pain (NRS)</b>	0.3 (-0.1 - 0.6)	0.2 (-0.2 – 0.5)	n.s.
<b>Fast stroke pain (NRS)</b>	0.3 (0.0 - 0.5)	0.2 (-0.2 – 0.5)	n.s.
<b>Arm pain threshold (kPa)</b>	176.1 (158.3 – 194.0)	162.2 (126.5 – 197.9)	n.s.
<b>Leg pain threshold (kPa)</b>	245.2 (217.2 – 273.2)	243.7 (190.0 – 297.4)	n.s.
<b>PCS</b>	25.1 (20.3 – 29.9)	20.7 (11.3 – 30.1) [9]	n.s.
<b>EQ-VAS</b>	47.3 (40.9 – 53.7)	52.4 (37.5 – 67.4) [9]	n.s.
<b>Pain DETECT</b>	25.0 (21.5 – 28.5) [14]	21.3 (16.8 – 25.9) [6]	n.s.
<b>Lingering Pain at 1 Day (%)</b>	82.3 [19/23]	75.0% [6/8]	n.s.
<b>Lingering Pain at 5 Days (%)</b>	47.8 [11/23]	42.9% [3/7]	n.s.


**Table 2 – Descriptive Quantitative Sensory Testing (Brushstroke) Data**

Pleasantness is displayed on a numerical rating scale (NRS) -5 [very unpleasant] to 5 [very pleasant], pain on an NRS of 0-10. Lingering pain is the pain felt at the examination site post examination. Mean values are represented with 95% confidence intervals in parenthesis. Where group size varied this is displayed in square brackets. Abbreviations: FIQR = Fibromyalgia impact questionnaire revised; WPI = Widespread pain index; SSS = Symptom severity score; PCS = Pain catastrophising scale rating; EQ-VAS - EuroQual visual analogue scale rating. Statistical significance tested with a Mann Whitney U test. Uncorrected p value set at 0.05; n.s., not significant. A Bonferroni correction was made for multiple tests in the hypothesis; after 15 tests p<0.003).


### a Pain Medicine




### b Page 24 of 31




### c Brushstroke Pleasantness



### d Brushstroke Ticklishness




### e Brushstroke Pain






## Frequency of Brushstroke After-sensations



HC n = 16



FMS n = 44

\*\*\* p<0.001

□ nAS

▒ nUAS

■ UAS

## Character of Brushstroke After-sensations in FMS

